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ABSTRACT: Synthetic molecules that bind sequence-specifically to DNA have been developed for varied biological appli-
cations, including anticancer activity, regulation of gene expression, and visualization of specific genomic regions. Increas-
ing the number of base pairs targeted by synthetic molecules strengthens their sequence specificity. Our group has been 
working on the development of pyrrole–imidazole polyamides that bind to the minor groove of DNA in a sequence-specific 
manner without causing denaturation. Recently, we reported a simple synthetic method of fluorescent tandem dimer pol-
yamide probes composed of two hairpin moieties with a linking hinge, which bound to 12 bp in human telomeric repeats 
(5–(TTAGGG)n–3) and could be used to specifically visualize telomeres in chemically fixed cells under mild conditions. 
We also performed structural optimization and extension of the target base pairs to allow more specific staining of telo-
meres. In the present study, we synthesized tandem tetramer polyamides composed of four hairpin moieties, targeting 24 
bp in telomeric repeats, the longest reported binding site for synthetic, non-nucleic-acid-based, sequence-specific DNA-
binding molecules. The novel tandem tetramers bound with a nanomolar dissociation constant to 24 bp sequences made 
up of four telomeric repeats. Fluorescently labeled tandem tetramer polyamide probes could visualize human telomeres in 
chemically fixed cells with lower background signals than polyamide probes reported previously, suggesting that they had 
higher specificity for telomeres. Furthermore, high-throughput sequencing of human genomic DNA pulled down by the 
biotin-labeled tandem tetramer polyamide probe confirmed its effective binding to telomeric repeats in the complex chro-
matinized genome. 
Introduction 
Sequence-specific DNA binding molecules have poten-
tial as DNA-based therapeutics and diagnostics. Various 
kinds of programmable, sequence-specific DNA-binding 
molecules have been developed, including the clustered 
regularly interspaced short palindromic repeats 
(CRISPR)/CRISPR-associated caspase 9 (Cas9) systems,1 
protein-based zinc fingers,2 transcription activator-like ef-
fector (TALE),3 and nucleic-acid-based triplex-forming ol-
igonucleotides (TFO).4 Chemically modified nucleic acid 
analogues such as peptide nucleic acids (PNA) can also 
function as TFOs.5 Other synthetic, non-nucleic-acid-
based sequence-specific DNA-binding molecules have 
been reported, including amidine-benzimidazole-phenyl 
(ABP)-based minor groove binders,6 DNA-binding frag-
ments of transcription factors,7 threading polyintercala-
tors8 and minor groove-binding pyrrole–imidazole (Py–
Im) polyamides.9 Our group has been working on pyrrole–
imidazole (Py–Im) polyamides first described by Dervan 
and coworkers. Py–Im polyamides are composed of N-
methylpyrrole, N-methylimidazole, and aliphatic amino 
acids connected by amide bonds, and they bind sequence-
specifically to the minor groove of double-stranded B-DNA 
by recognizing Watson–Crick base pairs. The binding rule 
is that antiparallel arrangement of Im/Py can bind to G•C 
base pairs, whereas Py/Py can bind to both A•T and T•A 
base pairs.9f,g Referred to as aliphatic amino acid residues, 
the C-terminal -alanine tail and -aminobutyric acid or 
2,4-diaminobutyric acid (Dab) turn moiety, called a -turn, 
also binds to A•T and T•A base pairs.10 The -turn connects 
two aromatic peptides to form hairpin11 and cyclic12 struc-
tures, and the C-terminal -alanine tail increases sequence 
specificity and binding affinity.13a In contrast, internal -al-
anine can form /, /Py and /Im pairs as a substitution 
for Py rings and can relax the curvature of the polyamides 
to allow their efficient binding.13b Py–Im polyamides can be 
synthesized easily by machine-assisted solid-phase peptide 
 synthesis (SPPS)12d,14 and have been used for many pur-
poses; for example, visualization of specific sequences,15 
pull-down and identification of binding regions,16 inhibi-
tion of gene expression,17 transcriptional activation,18,19 and 
detection of specific sequences on a solid substrate.20 To 
target a single site in the whole human genome, which 
comprises about 3 billion base pairs, a sequence of  16 bp 
must be recognized by DNA-binding molecules; therefore, 
many efforts have been made to extend the target base-pair 
sequence of such DNA ligands. Wilson and coworkers suc-
ceeded in selectively targeting a 10 bp sequence with ABP 
motifs.6a Mascareñas and coworkers have recently synthe-
sized a DNA-binding peptide targeting 13 bp, which is com-
posed of the DNA-binding fragments of two transcription 
factors connected by a hook.7 Iverson and coworkers have 
developed threading polyintercalators, composed of naph-
thalene diimide intercalators and minor groove and major 
groove binding aliphatic linkers, which target 14 bp and 22 
bp.8 This 22 bp sequence was at that time the longest site 
recognized by a synthetic, non-nucleic-acid-based DNA 
binding molecule. Regarding Py–Im polyamides, a linear 
Py–Im polyamide monomer forming a homodimer with 
two molecules, and a cysteine-derived Py–Im polyamide 
dimer were both reported to bind to 16 bp sequences.21 Fur-
thermore, tandem hairpin motifs composed of several hair-
pin moieties with connecting hinge segments have also 
been demonstrated.22,23 
Recently, our group has designed tandem hairpin Py–Im 
polyamides specific for the human telomere repetitive se-
quences 5–(TTAGGG)n–3.23 The human telomere is com-
posed of tandem repeats of 5–TTAGGG–3 and the protein 
Figure 1. Chemical structures and schematic representations of tandem dimer TDi59–A and –B, TAMRA TDi59–A 
and –B and Biotin TDi59–A, tandem trimer TTri59–A and TAMRA TTri59–A, and tandem tetramer TTet59–A and –
B and TAMRA TTet59–A and –B and Biotin TTet59–B targeting for 12 bp, 18 bp, and 24 bp in human telomere se-
quence, respectively. 
 complex called shelterin including TRF1, TRF2, Rap1, TIN2, 
TPP1 and POT1. The telomere protects the ends of the 
chromosomes from nucleolytic degradation and DNA re-
combination and thus is important in chromosome stabil-
ity.24 Human telomere DNA has a duplex region and a sin-
gle-stranded 3 overhang, which is suggested to form G-
quadruplexes or t-loops.25 In normal mammalian cells, the 
number of telomere repeats decreases with cell division 
and is related to the aging process and cancer.24a,c,f There-
fore, the telomere length is an important biomarker in 
studies of these processes, and many techniques to visual-
ize telomeres and to measure telomere length have been 
reported.15b Fluorescence in situ hybridization (FISH) using 
fluorescent PNA probes has been widely used, but this 
method normally denatures the DNA under the harsh con-
ditions required for efficient probe binding to telomeres 
and can lead to destruction of telomere structures.26 In 
contrast, Py–Im polyamides can bind to target sequences 
under mild conditions and thus can visualize target regions 
without destroying their structures.23e Based on a previous 
report of visualization of telomeres and estimation of their 
length in chemically fixed cells with Texas Red-labeled Py–
Im polyamide probes,23a our group developed a simple 
method for synthesis of Py–Im polyamide probes labeled 
with 5–carboxytetramethylrhodamine (TAMRA) that 
bound to 12 bp of the human telomere sequences. The 
probes were named tandem dimer TDi59-A and TAMRA 
TDi59-A (Figure 1) and were synthesized from a fluorenyl-
methyloxycarbonyl (Fmoc) building block comprising the 
sequence from (R)-Dab to the N-terminus of a hairpin moi-
ety.23b-d Costaining with the fluorescent Py–Im polyamide 
probe and anti-TRF1 antibody under mild conditions con-
firmed that fluorescently labeled TDi59-A could specifi-
cally visualize human telomeres in chemically fixed cells 
and that telomere length is related to the amount of shel-
terin.23a,b To decrease the background signals from nonspe-
cific binding in telomere staining, we also developed 
TAMRA TDi59-B, containing hinge B lengthened by one 
methylene unit,23c and tandem trimer TAMRA TTri59-A, 
whose target sequence was extended to 18 bp, the longest 
specific sequence reported for Py–Im polyamides.23d Fur-
thermore the Py–Im polyamide probes can also visualize 
telomeres in tissue sections.23e 
In this study, we have synthesized, using an automatic 
solid-phase peptide synthesizer, novel tandem tetramer 
Py–Im polyamides TTet59-A and -B (Figure 1) targeting 24 
Scheme 1.  Solid–phase Synthesis of Tandem Tetramer Py–Im Polyamides and the Structure of Building Block 
1. 
Reagents and conditions: (i) 20% piperidine, DMF; (ii) Fmoc-PyIm-CO2H, HCTU, DIEA, NMP; (iii) 20% piperidine, 
DMF; (iv) Fmoc-Py-CO2H, HCTU, DIEA, NMP; (v) 20% piperidine, DMF; (vi) Fmoc-Py-CO2H, HCTU, DIEA, NMP; 
(vii) 20% piperidine, DMF; (viii) 1, HCTU, DIEA, NMP; (ix) 20% piperidine, DMF; (x) Fmoc-mini-PEG or N-Fmoc-Am-
ido-dPEG2 Acid, HCTU, DIEA, NMP; (xi) 20% piperidine, DMF; (xii) Fmoc-PyIm-CO2H, HCTU, DIEA, NMP; (xiii) 20% 
piperidine, DMF; (xiv) Fmoc-Py-CO2H, HCTU, DIEA, NMP; (xv) 20% piperidine, DMF; (xvi) Fmoc-Py-CO2H, HCTU, 
DIEA, NMP; (xvii) 20% piperidine, DMF; (xviii) 1, HCTU, DIEA, NMP; (xix) 20% piperidine, DMF; (xx) 3,3-diamino-N-
methyldipropylamine, 45 °C; (xxi) 5–carboxytetramethylrhodamine succinimidyl ester or EZ–Link NHS–PEG12–Biotin, 
DIEA, DMF. 
 bp in the human telomere 5–(TTAGGG)n–3 repeats. These 
Py–Im polyamides are composed of four hairpin units and 
three hinges, either A or B. To our knowledge, 24 bp is the 
new record for the longest binding site of synthetic, non-
nucleic-acid-based, sequence-specific DNA-binding mole-
cules. Surface plasmon resonance (SPR) analysis was per-
formed to assess the binding affinity to four telomere re-
peats of the two tandem tetramer Py–Im polyamides and 
tandem trimer TTri59-A. After conjugation of TTet59-A 
and -B with TAMRA to obtain TAMRA TTet59-A and -B, 
we stained telomeres in chemically fixed cells to compare 
the new Py–Im polyamide probes with those previously re-
ported and found that the background signals derived from 
nonspecific binding were much lower for the tetramers 
than for previously reported Py–Im polyamide probes. Fi-
nally, TDi59-A and TTet59-B were conjugated to biotin, 
allowing us to assess their binding to telomeric repeats in 
the whole genome using high-throughput sequencing 
technology.16f,g,27 
 
Results and Discussion 
Synthesis of Py–Im Polyamides. As shown in Scheme 
1, tandem tetramer Py–Im polyamides TTet59-A and -B 
were synthesized based on the reported methodology, us-
ing building block 1 corresponding to Dab and three-ring 
Py and Im beside the N-terminal.23b-d In detail, machine-
assisted Fmoc solid-phase peptide synthesis (SPPS) from 
Fmoc--Ala-Wang resin was performed. Fmoc-protected 
resin was treated with 20% piperidine/N,N-dimethylfor-
mamide (DMF) for deprotection, followed by coupling 
with the next Fmoc block (Fmoc-Py-OH, Fmoc-PyIm-
OH,28 1,23b-d Fmoc-mini-PEG or N-Fmoc-amido-dPEG2 
Acid) activated with N,N-diisopropylethylamine (DIEA) 
and N,N,N,N-tetramethyl-O-(6-chloro-1H-benzotriazol-1-
yl) uronium hexafluorophosphate (HCTU) in N-methyl-2-
pyrrolidone (NMP). After these two procedures were re-
peated 19 times, the N-terminal Fmoc-protected amino 
group was deprotected with 20% piperidine and then 
cleaved from the resin with 3,3-diamino-N-methyldiprop-
ylamine at 45 °C to produce TTet59-A and -B with 2.7% 
and 7.7% yield, respectively. The resulting Py–Im polyam-
ides were coupled with 5-carboxytetramethylrhodamine or 
biotin succinimidyl ester in DIEA and DMF to produce the 
fluorescent probes TAMRA TTet59-A and -B and the bio-
tinylated Py–Im polyamides Biotin TDi59-A and Biotin 
TTet59-B. Analytical high-performance liquid chromatog-
raphy (HPLC) profiles and electrospray ionization time-of-
flight mass (ESI-TOF-MS) spectrometry spectra are shown 
in Figures S1 and S2, respectively.  
Comparative Analysis of Binding to Match Sequence. 
Binding affinities of tetramers TTet59-A and -B and tan-
dem trimer TTri59-A to telomere repeats were assessed 
with SPR.23c,d,29 5-Biotinylated ODN-1 (5-biotin-
GGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGTTTTCCT
AACCCTAACCCTAACCCTAACCCTAACC-3) containing 
four telomeric repeats was immobilized to a sensor chip 
through a biotin–streptavidin interaction, and then the tri-
mer and tetramers were passed over the DNA on the sensor 
chip, and sensorgrams (shown in Figure S3) and values 
(summarized in Table 1) were obtained. The underlined ba-
ses are the binding site of these three types of Py–Im poly-
amides. Tetramer TTet59-A showed strong binding affinity 
to ODN-1 (KD = 7.5 nM), comparable to other types of Py–
Im polyamides.9 Trimer TTri59-A showed a slightly higher 
association constant and stronger binding affinity than 
TTet59-A (KD = 6.1 nM). As suggested previously,23d a major 
reason for this result is that the tetramer’s higher steric 
hindrance influenced its accessibility to the match site. Of 
the three Py–Im polyamides, TTet59-B showed the strong-
est binding affinity (KD = 4.0 nM), attributed to a much 
slower dissociation, suggesting that the hinge region pre-
vented the polyamide’s dissociation.  
Visualization of Human Telomeres to Compare Py–
Im Polyamide Probes. To compare the abilities of Py–Im 
polyamide probes to stain telomeres specifically, we dou-
bly stained human HeLa 1.3 cell spreads with 4,6-dia-
midino-2-phenylindole (DAPI) and five Py–Im polyamide 
probes: TAMRA TDi59-A and -B, TAMRA TTri59-A, and 
TAMRA TTet59-A and -B.23 Cell spreads are used for clin-
ical karyotyping tests and are prepared from colcemid-
treated mitotic cells fixed with MeOH/AcOH. The result-
ing images of chromosomes stained with 75 nM Py–Im pol-
yamide probes are shown in Figures 2 and S4A. Chromoso-
mal regions and nuclei were visualized with DAPI. Each 
Py–Im polyamide probe showed two foci at the ends of 
every chromosome, suggesting that all probes, including 
the new tandem tetramer probes TAMRA TTet59-A and -
B, could stain telomeres specifically. As the number of tar-
geted base pairs increased, the fluorescence of the polyam-
ide probes became lower, presumably because increasing 
the size of the polyamide probes decreased the number of 
molecules binding to telomeres, but the background sig-
nals derived from nonspecific binding of polyamides de-
creased. When treating cells with TAMRA TDi59-A or -B 
or TAMRA TTri59-A, we could easily observe the shape of 
chromosomes from the background signals of polyamides, 
and stronger background signals for TAMRA TDi59-A in 
particular were detected from the whole chromosomes. 
However, for treatment with TAMRA TTet59-A or -B, the 
intensity of background signals was less, showing that ex-
tending the target base pair sequence significantly im-
proves telomere specificity in cells. In addition, TAMRA 
TTet59-B had less background signal along the chromo-
somes than TAMRA TTet59-A, suggesting that the change 
Table 1. Binding Affinities of Polyamides TTet59–
A, TTet59–B and TTri59–A against Match Se-
quence (ODN–1) Calculated with SPR. 
 of hinge from A to B is also effective in improving specific-
ity; this was also shown by the comparison between 
TAMRA TDi59-A and -B.23c As shown in Figure 2B, 
TAMRA TTet59-B had the highest relative signal-to-noise 
(S/N) ratio. These results demonstrated that increasing the 
number of target base pairs to 24 and changing the hinge 
from A to B suppressed the nonspecific binding and al-
lowed us to observe telomeres in HeLa 1.3 cell spreads with 
high specificity.  
Images of telomere staining of HeLa 1.3 cells fixed in for-
maldehyde (Figures 3 and S4B), a commonly used fixation 
method in cell biology, and the quantitative analysis of S/N 
ratios (Figure 3B) suggested that the results were con-
sistent with those of cell spreads staining. Many sharp foci 
from the telomeric regions were observed in the nuclei of 
cells.23a,b As reported previously, TAMRA TDi59-B and 
TAMRA TTri59-A showed lower background signals than 
TAMRA TDi59-A.23c,d The background signals of the two 
tandem tetramer probes TAMRA TTet59-A and -B were 
lower and their S/N ratios were higher than the other three 
probes. As can be seen from the polyamide signals of 
TAMRA TTet59-A and -B shown in Figure 3, the shapes of 
the whole nuclei were less distinct. In the images of for-
maldehyde-fixed cells, TAMRA TTet59-B also showed the 
highest S/N ratio. These results also demonstrated that 
TAMRA TTet59-A and -B could visualize telomeres with 
higher specificity in the fixed cells or formaldehyde-fixed 
cells and that TAMRA TTet59-B targeting 24 bp and com-
posed of four hairpins and three B hinges had the highest 
telomere specificity of the fluorescent Py–Im polyamide-
based telomere probes. 
High-throughput Sequencing of the Binding Sites of 
Py–Im Polyamide Probes for Telomeric Repeats. Im-
ages of chromosome spreads treated with the Py–Im poly-
amide probes (Figure 2) suggested that they specifically 
stained telomeres. To assess their efficient binding to telo-
meric repeats in a biologically active, histone-packed, 
chromatinized genome, we performed high-throughput 
sequencing of DNA bound to Biotin TDi59-A and Biotin 
TTet59-B, based on the reported procedure.16f,g The work-
flow is shown in Scheme 2. In brief, nuclei were extracted 
from BJ fibroblast cells and then incubated with 400 nM 
Biotin TDi59-A or Biotin TTet59-B for 16 h at 4 °C. After 
this, the extracted nuclei were treated with micrococcal 
nuclease to produce mononucleosomes to generate the op-
timally sized DNA for construction of a sequencing library. 
Nuclear proteins were digested with proteinase K, and 
then DNA bound to the biotinylated Py–Im polyamide 
Figure 2. Telomere staining of HeLa 1.3 cell spreads 
with 75 nM fluorescent Py–Im polyamide probes. (A) 
The images of HeLa 1.3 cell spreads stained with DAPI 
(first row) and the fluorescent polyamide probes (sec-
ond row). The merged images are shown in the third 
row. Original images are shown in Figure S4A. (B) 
Distribution of relative signal-to-noise (S/N) ratio of 
telomeric foci in the images. 
Figure 3. Telomere staining of HeLa 1.3 cells with 15 
nM fluorescent Py–Im polyamide probes. (A) The im-
ages of HeLa 1.3 cells stained with DAPI (first row) 
and fluorescent polyamide probes (second row). The 
merged images are shown in the third row. Original 
images are shown in Figure S4B. (B) Distribution of 
signal-to-noise (S/N) ratio of telomeric foci in the im-
ages. 
 probes was extracted through a biotin–streptavidin inter-
action on streptavidin–coated magnetic beads (C1 beads). 
The extracted and purified DNA was ligated with sequenc-
ing platform-specific adapters and amplified with a poly-
merase chain reaction to obtain sufficient amounts for a 
sequencing library. The qualified libraries were sequenced 
using Ion Proton Sequencing system. Sequenced and fil-
tered reads were aligned to human reference genome hg38. 
MACS peaks were called to identify the differentially en-
riched regions compared with control data.30a 
Figure S5 shows a representative result indicating the en-
riched regions in chromosomes 1 and 18, and a close-up of 
the enriched telomeric repeats from a non-treated control 
sample and after Biotin TDi59-A and Biotin TTet59-B 
treatment is shown in Figure 4. In both left and right arm 
termini of chromosomes 1 and 18, we observed significant 
enrichments with both polyamides compared with the 
control. The enrichment was consistent with telomeric re-
peat sequences (TTAGGG/CCCTAA) of the reference ge-
nome, suggesting that we could successfully validate the 
binding of Biotin TDi59-A and Biotin TTet59-B to telo-
meric repeats with high-throughput sequencing. Other 
mild enrichments appeared to be the results of partial or 
non–specific binding. 
The enrichments in the termini of each chromosome are 
shown in Figure S6. Duplicate experiments ensured the 
consistency of enrichments in chromosomal termini. How-
ever, we could not quantify the enrichment level on Chr 3R, 
5R, 6L, 6R, 8L, 8R, 9R, 11L, 13L, 14L, 14R, 15L, 16R, 17L, 19L, 
20L, 20R, 21L and 22L (L- left arm, R- right arm) chromo-
somal termini. This may be because of lacking telomeric 
repeat sequences information on the above mentioned 
chromosomes in the human reference genome hg38 data. 
Even though chromosomes 13, 14, 15, 21 and 22 lack the te-
lomeric repeats information at the left termini presumably 
because of rDNA whose sequences are not included in the 
human reference genome hg38, we could observe enrich-
ments from ~16000000 bp, ~16000000 bp, ~17000000 bp, 
~5010000 bp and ~10510000 bp, respectively. These results 
show that Biotin TDi59-A and Biotin TTet59-B could ef-
fectively recognize and bind to telomeric repeats. 
To identify high affinity binding motif of Biotin TDi59-
A and Biotin TTet59-B from the enrichments, we used the 
Homer motif analysis program with the enriched peaks.30b 
One of the highly enriched motifs corresponded to telo-
meric 5–(TTAGGG)n–3 repeats with a p value of e–8595 and 
e–100 for Biotin TDi59-A and Biotin TTet59-B, respectively. 
(Figure 4B). This result also suggests efficient binding of 
Biotin TDi59-A and Biotin TTet59-B to telomeres. 
Finally, to compare the recognition of telomeric repeats 
by Biotin TDi59-A with that by Biotin TTet59-B, the ratio 
of reads containing  4 TTAGGG/CCCTAA repeats to 
whole sequenced reads was calculated. As shown in Figure 
4C, the ratio for Biotin TDi59-A was 18.2 times higher than 
the nontreated control, showing that Biotin TDi59-A 
could enrich telomeric DNA. The ratio for Biotin TTet59-
B was 1.9 times higher than that for Biotin TDi59-A, sug-
gesting that TTet59-B exhibited better recognition ability 
toward telomeric repeats. This result is also consistent with 
the higher telomere-specific staining of TAMRA TTet59-B. 
High-throughput sequencing confirmed the binding of 
Biotin TDi59-A and Biotin TTet59-B to telomeric repeats 
in the whole genome. In contrast, foci of fluorescently la-
beled Py–Im polyamide probes were specifically detected 
at the end of the chromosomes (Figure 2). The principal 
reason for this is that accumulation of the Py–Im polyam-
ides on long telomeric repeats in telomere regions was 
higher than that in nonspecific regions, and therefore 
much stronger fluorescence was detected at the termini of 
chromosomes than from other chromosomal regions. 
Conclusion 
In this study, we have synthesized novel tandem te-
tramer Py–Im polyamides composed of 4 hairpins and 3 
hinges that targeted 24 bp of the human telomere se-
quences. This is a new record for the longest binding site 
of synthetic, non-nucleic-acid-based, sequence-specific 
Scheme 2.  Extraction and High–throughput Sequencing of Genomic DNA Bound by Biotinylated Py–Im Poly-
amide Probes. 
 DNA-binding molecules. SPR analysis revealed that tan-
dem tetramers could bind to four telomeric repeats with 
nanomolar KD values. TAMRA-labeled tandem tetramer 
Py–Im polyamide probes could stain clearly the telomere 
foci in chemically fixed cells. Compared with previously re-
ported tandem dimer and trimer Py–Im polyamides, the 
tandem tetramers had higher specificity for telomeres in 
cells, and TAMRA TTet59-B containing hinge B had the 
highest specificity. Furthermore, high-throughput se-
quencing of chromatin pulled down by biotin-labeled Py–
Im polyamide probes confirmed their high recognition and 
binding toward telomeric DNA. To the best of our 
knowledge, this is the first report of high-throughput se-
quencing of DNA pulled down by a synthetic DNA binder 
targeting human telomeres. To allow the application of 
these tetramers, our group continues to optimize further 
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Materials and Methods 
Materials.  HPLC analysis for chasing each solution–phase reaction and checking 
each product was performed on a PU–2089 plus series system (JASCO) using 
CHEMCOBOND 4.6 mm x 150 mm 5–ODS–H Column (Chemco Plus Scientific Co., 
Ltd.) in 0.1% TFA in water with acetonitrile as the eluent at a flow rate of 1.0 mL/min 
and a linear gradient elution of 0 to 50% acetonitrile in 20 min with detection at 254 nm. 
Purification of Py–Im polyamides were done with reversed–phase HPLC performed on 
a UV2075 HPLC UV/VIS detector and a PU–2080 plus series system (JASCO) using 
CHEMCOBOND 4.6 mm x 150 mm 5–ODS–H Column in 0.1% TFA in water with 
acetonitrile as the eluent at a flow rate of 1.0 mL/min. Collected fractions were 
lyophilized and then analyzed by ESI–TOF–MS (Bruker). For the collect mass 
measurement, external mass calibration (m/z: 622.0290 and 922.0098), purchased from 
Agilent Technologies, was used. Fmoc-mini-PEG and N-Fmoc-Amido-dPEG2 Acid 
were purchased from Peptide International. Fmoc-Py-CO2H, DMF used for solid–phase 
synthesis, NMP, trifluoroacetic acid (TFA), and piperidine were from Wako. HCTU 
was from Peptide Institute, Inc. Fmoc--Ala-Wang resin (0.60 mmol/g, 100–200 mesh) 
was from Novabiochem. DIEA was from Nacalai Tesque, Inc. DMF used for solution–
phase synthesis and for telomere–staining and acetonitrile were from Kanto Chemical 
Co., Inc. 3, 3’-diamino-N-methyldipropyl-amine was from Tokyo Chemical Industry 
Co., Ltd. 5–carboxytetramethylrhodamine succinimidyl ester and EZ–Link NHS–
PEG12–Biotin were from Thermo Fisher Scientific Inc. The Fmoc units 11a,b and Fmoc-
PyIm-CO2H
2 were synthesized using the previous method. TAMRA TDi59–B was 
purchased from HiPep Laboratories. TAMRA TDi59–A, TTri59–A and TAMRA 
TTri59–A were synthesized following the previous methodology.1b,c Solid–phase 
peptide synthesis was performed on a PSSM–8 (Shimadzu). Concentrations of Py–Im 
Polyamides were calculated with a Nanodrop ND–1000 spectrophotometer (Thermo 
Fisher Scientific Inc.) using an extinction coefficient of 9900 M−1cm−1 per one pyrrole 
or imidazole moiety at λmax near 310 nm. The SPR assays were performed using a 
BIACORE X instrument (GE Healthcare) with 5’–biotinylated DNA oligonucleotides 
(JBioS), streptavidin–coated sensor chip SA (GE Healthcare) and HBS–EP buffer (GE 
Healthcare). Cell images were recorded with DeltaVision (Applied Precision). HeLa 1.3 
cells were generous gifts of Dr T. de Lange (Rockefeller University) and BJ fibroblast 
cells were purchased from ATCC. DMEM medium and streptavidin–coated magnetic 
beads were purchased from Invitrogen. Normal goat serum (NGS) was from Millipore. 
Paraphenylene diamine, Triton X–100 and protease inhibitor cocktail were from Sigma. 
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DAPI was from Roche. MNase was from TaKaRa Bio Inc. Nonidet P–40 was from 
Nacalai Tesque, Inc. PCR purification kit was from Qiagen. Quality and quantity check 
of sequencing library was performed with Agilent 2100 Bioanalyzer and High 
sensitivity BioAnalyzer kit (Agilent Technologies). High throughput sequencing was 
performed with Ion ProtonTM Sequencer (Thermo Fisher Scientific Inc.). All other 
solvents and materials were from standard suppliers (highest quality available). 
 
General Procedures of Solid–phase Synthesis of Tandem Tetramer Py–Im 
Polyamides. Following the reported condition,1c each Fmoc solid–phase peptide 
synthesis (SPPS) of tandem tetramers was performed with a computer–assisted 
operation system under low humidity (< 20%). Fmoc units in each step were as follows: 
Fmoc-Py-CO2H (77 mg, 0.21 mmol), Fmoc-PyIm-CO2H (70 mg, 0.14 mmol), Fmoc-D-
Dab(ImImPy)-OH (1) (70 mg, 0.10 mmol), Fmoc-mini-PEG (81 mg, 0.21 mmol) and 
N-Fmoc-Amido-dPEG2 Acid (84 mg, 0.21 mmol). Before SPPS, each Fmoc unit was 
dissolved in NMP (1.0 mL) with HCTU and the amount of HCTU for Fmoc-Py-CO2H, 
Fmoc-PyIm-CO2H, 1, Fmoc-mini-PEG and N-Fmoc-Amido-dPEG2 Acid was 88 mg 
(0.21 mmol), 60 mg (0.15 mmol), 40 mg (0.097 mmol), 88 mg (0.21 mmol) and 88 mg 
(0.21 mmol), respectively. Fmoc--Ala-Wang resin swelled with NMP was loaded in 
the reaction vessel. 
Procedures were as follows: twice deblocking for 4 min with 20 % piperidine/ DMF 
(500 L), addition of 10% DIEA/NMP (364 L, DIEA was 0.21 mmol) to Fmoc unit-
HCTU mixture for activation, coupling for 60 min. Five times washing with DMF were 
performed during each step. After the last coupling, the deblocking of amino group at -
turn was performed. All couplings were carried out with a single-coupling cycle. All 
lines were purged with solution transfers and bubbled by nitrogen gas for stirring the 
resin. 
After SPPS, Py–Im polyamides on resin were cleaved with 3,3’-diamino-N-
methyldipropylamine at 45 °C for 3 h. The resin was removed by filtration and washed 
thoroughly with dichloromethane, and the filtrate was concentrated in vacuo.  The 
residue was dissolved in 1.0–2.0 mL dichloromethane-methanol mixture and then more 
than 10-fold volume of diethyl ether was added, followed by the centrifuge and removal 
of the supernatant. This process was repeated a few times until white precipitation was 
obtained. The obtained crude products were purified by reversed–phase HPLC in 0.1% 
TFA in water with acetonitrile as the eluent at a flow rate of 1.0 mL/min and a linear 
gradient elution of 25 to 55% acetonitrile in 40 min. Collected fractions were 




Synthesis of TTet59–A. Solid–phase synthesis was performed with 42.0 mg Fmoc–
–Wang resin (0.60 mmol/ g) and finally TTet59–A (3.0 mg, 6.8 x 10–4 mmol, 2.7% 
yield) was obtained as a pale yellow solid. Analytical HPLC: tR = 16.9 min. ESI–TOF–
MS m/z calcd for C200H246N79O42
5+ [M + 5H]5+ 885.1903 found 885.1820.  
 
Synthesis of TTet59–B. Solid–phase synthesis was performed with 43.0 mg Fmoc–
–Wang resin (0.60 mmol/ g) as a pale yellow solid. The resulting crude polyamide was 
purified as described to afford TTet59–B (8.9 mg, 2.0 x 10–3 mmol, 7.7% yield). 
Analytical HPLC: tR = 17.1 min. ESI–TOF–MS m/z calcd for C203H252N79O425+ [M + 
5H]5+ 893.5997 found 893.5936. 
 
Synthesis of TAMRA TTet59–A. TTet59–A (0.9 mg) and 5–carboxytetramethyl-
rhodamine succinimidyl ester (0.2 mg) were dissolved in DMF (250 L) and DIEA 
(0.40 L), followed by mixing at room temperature with shielding the light. After 
checking this reaction had been finished, the reaction mixture was purified by reversed–
phase HPLC in 0.1% TFA in water with acetonitrile as the eluent at a flow rate of 1.0 
mL/min and a linear gradient elution of 30 to 70% acetonitrile in 30 min, followed by 
lyophilization of the collected fractions to afford TAMRA TTet59–A (1.1 mg) as a 
purple powder. Analytical HPLC: tR = 18.2 min. ESI–TOF–MS m/z calcd for 
C225H267N81O46
6+ [M + 6H]6+ 806.5169 found 806.5205. 
 
Synthesis of TAMRA TTet59–B. TTet59–B (2.6 mg) and 5–carboxytetramethyl-
rhodamine succinimidyl ester (0.9 mg) were dissolved in DMF (272 L) and DIEA 
(0.60 L). The reaction and purification were performed as described above to afford 
TAMRA TTet59–B (2.0 mg) as a purple powder. Analytical HPLC: tR = 18.3 min. 
ESI–TOF–MS m/z calcd for C228H274N81O467+ [M + 7H]7+ 697.4508 found 697.4565.  
 
Synthesis of Biotin TDi59–A. TDi59–A (1.9 mg) and EZ–Link NHS–PEG12–Biotin 
0.9 mg were dissolved in DMF (159 L) and DIEA (0.30 L). The reaction and 
purification were performed as described above to afford Biotin TDi59–A (0.4 mg) as a 
white solid. Analytical HPLC: tR = 17.4 min. ESI–TOF–MS m/z calcd for 
C139H198N44O35S
4+ [M + 4H]4+ 768.8691 found 768.8644. 
 
Synthesis of Biotin TTet59–B. TTet59–B (0.8 mg) and EZ–Link NHS–PEG12–
Biotin 0.1 mg were dissolved in DMF (101 L) and DIEA (0.20 L). The reaction and 
purification were performed as described above to afford Biotin TTet59–B (0.5 mg) as 
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a white solid. Analytical HPLC: tR = 19.0 min. ESI–TOF–MS m/z calcd for 
C240H321N82O57S
7+ [M + 7H]7+ 756.4918 found 756.4987. 
 
SPR Assays. The SPR assays were performed as described in previous reports.1b,c 
Biotinylated DNA was immobilized to streptavidin–coated sensor chip at a flow rate of 
10 L/min to obtain the desired immobilization level (up to approximately 1000 RU 
rise). The assays were performed with HBS–EP (10 mM HEPES pH 7.4, 150 mM NaCl, 
3 mM EDTA, 0.005% v/v Surfactant P20) containing 0.1% DMSO at 25 °C. A series of 
sample solutions with various concentrations were prepared in HBS–EP buffer 
containing 0.1% DMSO and injected at a flow rate of 20 L/min. To calculate 
association rates (ka), dissociation rates (kd), and dissociation constants (KD), data 
processing was performed with 1:1 binding with mass transfer model using 
BIAevaluation 4.1 program.  
 
Telomeres Staining and Calculation of S/N Ratios 
HeLa 1.3 Cell Spreads Treated with Fluorescent Py–Im polyamide Probes.1,3 
HeLa 1.3 cells were maintained in DMEM medium containing 10% fetal bovine serum 
(FBS) at 37 °C (5% CO2). HeLa 1.3 cells were blocked mitotically by adding 
0.2 µg/mL colcemid and incubated overnight. The cells were then swollen by treatment 
with hypotonic buffer (0.075 M KCl) for 15 min at room temperature, fixed with 
methanol/acetic acid (3:1) solution for 5 min. After centrifugation, cell pellet was again 
suspended in the methanol/acetic acid (3:1) solution. The cell suspension was spread on 
coverslips and air–dried at room temperature for 5 min and then at 60 °C for 30 min. 
The cell spread coverslips were kept at 4 °C until use.    
The dried spread coverslips were soaked in HEN buffer (10 mM HEPES pH 7.5, 1 
mM EDTA and 100 mM NaCl) over night at 4 °C before use. For blocking, the spread 
coverslips were treated with 10% NGS in TE buffer 1 (10 mM Tris–HCl pH 7.5, 1 mM 
EDTA) for 30 min at room temperature. After brief washing with TE buffer 1, the 
spread coverslips were incubated with 10% NGS, 75 nM fluorescent Py–Im polyamide 
probe and 0.5 µg/ml DAPI in TE buffer 1 containing 10% DMF for 1 h at 37 °C. After 
washing with TEN100 (10 mM Tris–HCl pH 7.5, 1 mM EDTA and 100 mM NaCl) 
buffer (five times for 3 min), the spread coverslips were mounted in PPDI solution 
(10 mM HEPES pH 7.5, 100 mM KCl, 1 mM MgCl2, 80% glycerol, 1 mg/mL 
paraphenylene diamine) and the coverslips were sealed with a nailporish. Sectioning 
images were recorded with DeltaVision and projected (“Quick Projection” tool) without 
deconvolution to obtain telomeric signals and background signals. For quantification of 
the telomere signals in Figure 2, the telomere signals yielded by the polyamides were 
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extracted based on threshold values using the Softworks software (Applied Precision). 
The maximum intensity values of signals in the extracted telomere regions were then 
used as telomere signals. For the background signals, ROIs which were same shape of 
each telomere were set next to the defined each telomere signals in the chromosomes, 
and maximum values of the signals were used as background signals. Box plot and dot 
plot were created in R software. 
 
Formaldehyde–fixed HeLa 1.3 Cells Treated with Fluorescent Py–Im Polyamide 
Probes.1 For polyamide staining, the HeLa 1.3 cells were grown on coverslips coated 
with polylysine. The cell coverslips were washed in phosphate–buffered saline (PBS) 
twice and fixed with 1.85% formaldehyde in PBS for 15 min at room temperature. The 
fixed cell coverslips were then treated with 50 mM glycine in PBS for 5 min, and 
permeabilized with 0.5% Triton X–100 in PBS for 5 min. After briefly washing with 
HMK buffer (10 mM HEPES pH 7.5, 1 mM MgCl2, 100 mM KCl) twice, the coverslips 
were soaked in HEN buffer for overnight and kept at 4 °C until use. For blocking, the 
cell coverslips were treated with 10% NGS in TE buffer 1 for 30 min at room 
temperature. After brief washing with TE buffer 1, the cell coverslips were incubated 
with 10% NGS, 15 nM fluorescent Py–Im polyamide probe and 0.5 µg/ml DAPI in TE 
buffer 1 containing 10% DMF for 1 h at 37 °C. After washing with TEN200 buffer (10 
mM Tris–HCl pH 7.5, 1 mM EDTA, and 200 mM NaCl) (five times for 3 min), the 
mounting and subsequent image acquisitions were performed as described above. For 
quantification of the telomere signals in Figure 3, they were extracted from the images 
as described previously.1 The telomere signals yielded by the polyamides were 
extracted based on threshold values using the Softworks software (Applied Precision). 
The maximum intensity values of signals in the extracted telomere regions were then 
used as telomere signals. For the background signals, 10 squares (10 pixels x 10 pixels) 
were randomly set outside the defined telomere signals and mean values of the signals 
in the squares were used as background signals. Box plot and dot plot were created in R 
software. 
 
Identification of TDi59-A and TTet59-B Binding Sites in Genome 
Pull–down and Affinity Purification of DNA bound by Biotin TDi59–A and Biotin 
TTet59–B.4 Human foreskin BJ fibroblast cells were maintained in 8 mL DMEM 
medium containing 10% FBS, 1x non–essential amino acids, penicillin (100 units/mL) 
and streptomycin (100 g/mL) at 37 °C (5% CO2). 75–80% confluent cells (2 x 106 
cells) were washed with PBS and isolated by tripsinization for 3 min. 3 plates of 2 x 106 
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cells were used. Each isolated 2 x 106 cells were again washed with cold PBS and the 
cell pellet was suspended in 5 mL ice cold NP–40 lysis buffer (10 mM Tris–HCl pH 7.4, 
10 mM NaCl, 3 mM MgCl2, 0.5% Nonidet P–40, 0.15 mM spermine, 0.5 mM 
spermidine and 0.015x protease inhibitor cocktail) and incubated on ice for 5 min. The 
nuclei were pelleted by centrifugation at 300 g for 10 min and then carefully dissolved 
in 900 L binding buffer (10 mM Tris–HCl pH 8.0, 5 mM MgCl2, 1 mM Dithiothreitol, 
0.3 M KCl, 0.3x protease inhibitor cocktail and 10% glycerol)4b and incubated at 4 °C 
for 1 h. 100 L of the binding buffer containing 1 L of 400 M biotinylated Py–Im 
polyamide probe dissolved in DMSO was added to the extracted nuclei solution. Each 2 
x 106 cells nuclei were incubated with biotinylated Py–Im polyamide probe (400 nM 
final concentration) dissolved in DMSO (0.1% final concentration) at 4 °C for 16 h. 
After incubation, the nuclei were pelleted by centrifugation at 5200 rpm for 10 min and 
then washed with 1 mL washing buffer A (10 mM Tris–HCl pH 7.4, 15 mM NaCl, 60 
mM KCl, 0.15 mM spermine, 0.5 mM spermidine and 0.1x protease inhibitor cocktail). 
After removal of washing buffer A by centrifuge at 5200 rpm for 10 min, the pellets 
were resuspended in 50 L MNase buffer (20 mM Tris–HCl pH 8.0, 5 mM NaCl, 2.5 
mM CaCl2). Then 4 units micrococcal nuclease (MNase) in 50 L MNase buffer 
containing 43 g RNase A and 0.2x protease inhibitor cocktail was added to the 
solution, followed by incubation at 37 oC for 30 min to digest to mononucleus.4b After 
this digestion 2 L of 0.5 M EDTA was added to quench MNase and then histone 
protein was removed by addition of 4 L of 20 mg/mL proteinase K solution and 
incubation at 37 oC for 30 min. After MNase digestion and proteinase K treatment, the 
suspension was mixed with equal volume of modified COSMIC4a buffer (20 mM Tris–
HCl pH 8.1, 2 mM EDTA, 150 mM NaCl, 0.3x protease inhibitor cocktail, 1% Triton–
X 100, and 0.1% SDS) containing 0.50 mg of suspended streptavidin–coated magnetic 
beads (C1 beads) and then incubated at 4 °C for 20 h to pull down target DNA. 
Preparation of the beads was performed as follows: after removing the suspension 
solution from Dynabeads® MyOne™ Streptavidin C1, they were washed with modified 
COSMIC buffer and resuspended in it.  
After the pull down, beads–bound DNA was isolated by reported affinity 
purification.4 Beads were washed once with 500 L of washing buffer 1 (10 mM Tris–
HCl pH 8.0, 1 mM EDTA, 0.3% SDS) for 7 min, once with 500 L of washing buffer 2 
(10 mM Tris–HCl pH 8.0, 250 mM LiCl, 1 mM EDTA, 0.5% Nonidet P–40) for 5 min, 
twice with 500 L washing buffer 3 (10 mM Tris–HCl pH 7.5, 1 mM EDTA, 0.1% 
Nonidet P–40) for 5 min and twice with 500 L TE buffer 2 (10 mM Tris–HCl pH 8.0 
and 1 mM EDTA) for 5 min. Beads were resuspended in elution buffer 1 (10 mM Tris–
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HCl pH 7.6, 0.4 mM EDTA and 100 mM KOH) and DNA was eluted from magnetic 
beads after heating at 90 °C for 30 min. The remaining DNA with the beads was eluted 
using elution buffer 2 (2% SDS, 100 mM NaHCO3 and 3 mM biotin) with the heating at 
65 oC for 8 h. The detached DNA was purified with QIAquick PCR Purification Kit 
following the manufacture protocol and then quantified with a Nanodrop. Isolated DNA 
were pooled to get optimum DNA concentration for the sequencing library construction. 
Biological replicates were assessed. 
High–throughput Sequencing.4b Sequencing libraries of the collected DNA were 
prepared with standard Ion XpressTM Plus gDNA Fragment Library Preparation 
reagents (Thermo Fisher Scientific Inc.). A1 and P1 adapter–ligated enriched DNA was 
amplified and purified, followed by quality and quantity check with Agilent 2100 
Bioanalyzer. The qualified libraries were used for high–throughput sequencing. 
Following the manufacture’s protocol, the sequencing was performed, starting with 
template preparation using Ion PITM template OT2 200 kit in Ion one touch2 system 
(Thermo Fisher Scientific Inc.). The templates were then enriched using Ion one touch 
ES. The enriched libraries were sequenced with 300 flow of single read by Ion ProtonTM 
Sequencer using Ion PITM Sequencing 200 kit v3/ Ion PI chip by following the 
manufacturer’s guidelines. 25–30 million post filtered reads per library were produced. 
The data were handled by employing standard program packages in the Ion torrent suit. 
Torrent Mapping Alignment Program 4.4.2 (TMAP) was used for aligning reads with 
the hg38 reference genome, and enriched peaks was called using MACS 1.4.2.5a The 
enriched genomic regions were visualized using UCSC genome browser 





Figure S1. Analytical HPLC profiles of Py–Im polyamides (A: TTet59–A, B: TTet59–





Figure S2. ESI–TOF MS spectra of Py–Im polyamides (A: TTet59–A, B: TTet59–B, 





Figure S3. SPR sensorgrmas for the interaction between ODN-1 and (A) TTet59–A, 




Figure S4. Full images of HeLa 1.3 cell spreads in Figure 2 and HeLa 1.3 cells in 
Figure 3. Enlarged images of the boxed regions in (A) and (B) are shown in Figure 2 






Figure S5. Mapping of the biotinylated Py–Im polyamide probes binding and enriched 
























Figure S6. The enrichment of Biotin TDi59–A and Biotin TTet59–B at both termini 
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